Back to top
more

Omnicell (OMCL)

(Real Time Quote from BATS)

$30.89 USD

30.89
49,397

-0.20 (-0.64%)

Updated Aug 7, 2025 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Omnicell (OMCL) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Best Momentum Stocks to Buy for October 4th

by Zacks Equity Research

OMCL and SFBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 4, 2024.

Zacks Equity Research

New Strong Buy Stocks for October 4th

by Zacks Equity Research

KUBTY, OMCL, PDFS, RYAAY and HTH have been added to the Zacks Rank #1 (Strong Buy) List on October 4, 2024.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

Should You Continue to Retain OMCL Stock in Your Portfolio Now?

by Zacks Equity Research

Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Earnings Estimates Moving Higher for Omnicell (OMCL): Time to Buy?

by Zacks Equity Research

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Omnicell (OMCL) Introduces Central Med Automation Service

by Zacks Equity Research

Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.

Zacks Equity Research

Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.

Zacks Equity Research

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 218.75% and 9.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Omnicell (OMCL) Banks on Product Launches, Global Growth

by Zacks Equity Research

Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.

Zacks Equity Research

Here's Why Omnicell (OMCL) Should be in Your Portfolio Now

by Zacks Equity Research

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

Zacks Equity Research

Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?

by Zacks Equity Research

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Omnicell (OMCL) Gains From New Offerings Amid Cost Woes

by Zacks Equity Research

With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y

by Zacks Equity Research

Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GE HealthCare Technologies (GEHC) Meets Q1 Earnings Estimates

by Zacks Equity Research

GE HealthCare (GEHC) delivered earnings and revenue surprises of 0% and 3.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.

Zacks Equity Research

Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.

Zacks Equity Research

Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.

Zacks Equity Research

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

by Zacks Equity Research

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Zacks Equity Research

Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.